These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25147929)

  • 1. Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).
    Gentry PR; Kokubo M; Bridges TM; Noetzel MJ; Cho HP; Lamsal A; Smith E; Chase P; Hodder PS; Niswender CM; Daniels JS; Conn PJ; Lindsley CW; Wood MR
    J Med Chem; 2014 Sep; 57(18):7804-10. PubMed ID: 25147929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms of Action of M5 Muscarinic Acetylcholine Receptor Allosteric Modulators.
    Berizzi AE; Gentry PR; Rueda P; Den Hoedt S; Sexton PM; Langmead CJ; Christopoulos A
    Mol Pharmacol; 2016 Oct; 90(4):427-36. PubMed ID: 27461343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).
    Gentry PR; Kokubo M; Bridges TM; Kett NR; Harp JM; Cho HP; Smith E; Chase P; Hodder PS; Niswender CM; Daniels JS; Conn PJ; Wood MR; Lindsley CW
    J Med Chem; 2013 Nov; 56(22):9351-5. PubMed ID: 24164599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Optimization of Potent and CNS Penetrant M
    Bender AM; Cho HP; Nance KD; Lingenfelter KS; Luscombe VB; Gentry PR; Voigtritter K; Berizzi AE; Sexton PM; Langmead CJ; Christopoulos A; Locuson CW; Bridges TM; Chang S; O'Neill JC; Zhan X; Niswender CM; Jones CK; Conn PJ; Lindsley CW
    ACS Chem Neurosci; 2018 Jul; 9(7):1572-1581. PubMed ID: 29678111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Activity Relationships of Pan-Gα
    Berizzi AE; Bender AM; Lindsley CW; Conn PJ; Sexton PM; Langmead CJ; Christopoulos A
    ACS Chem Neurosci; 2018 Jul; 9(7):1818-1828. PubMed ID: 29683647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Muscarinic Acetylcholine Receptor M
    Bender AM; Garrison AT; Lindsley CW
    ACS Chem Neurosci; 2019 Mar; 10(3):1025-1034. PubMed ID: 30280567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.
    Bridges TM; Kennedy JP; Cho HP; Breininger ML; Gentry PR; Hopkins CR; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2010 Jan; 20(2):558-62. PubMed ID: 20004578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and structure-activity relationships study of positive allosteric modulators of the M
    Tanaka H; Negoro K; Koike T; Tsukamoto I; Yokoyama K; Maeda J; Inagaki Y; Shimoshige Y; Ino K; Ishizu K; Takahashi T
    Bioorg Med Chem; 2020 Jul; 28(13):115531. PubMed ID: 32386953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.
    Kurata H; Gentry PR; Kokubo M; Cho HP; Bridges TM; Niswender CM; Byers FW; Wood MR; Daniels JS; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2015 Feb; 25(3):690-4. PubMed ID: 25542588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe.
    Gentry PR; Kokubo M; Bridges TM; Cho HP; Smith E; Chase P; Hodder PS; Utley TJ; Rajapakse A; Byers F; Niswender CM; Morrison RD; Daniels JS; Wood MR; Conn PJ; Lindsley CW
    ChemMedChem; 2014 Aug; 9(8):1677-82. PubMed ID: 24692176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.
    Bridges TM; Marlo JE; Niswender CM; Jones CK; Jadhav SB; Gentry PR; Plumley HC; Weaver CD; Conn PJ; Lindsley CW
    J Med Chem; 2009 Jun; 52(11):3445-8. PubMed ID: 19438238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel, CNS penetrant M
    Bewley BR; Spearing PK; Weiner RL; Luscombe VB; Zhan X; Chang S; Cho HP; Rodriguez AL; Niswender CM; Conn PJ; Bridges TM; Engers DW; Lindsley CW
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4274-4279. PubMed ID: 28866269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).
    Wenthur CJ; Morrison R; Felts AS; Smith KA; Engers JL; Byers FW; Daniels JS; Emmitte KA; Conn PJ; Lindsley CW
    J Med Chem; 2013 Jun; 56(12):5208-12. PubMed ID: 23718281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Negative Allosteric Modulation of M
    Gould RW; Gunter BW; Bubser M; Matthews RT; Teal LB; Ragland MG; Bridges TM; Garrison AT; Winder DG; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2019 Aug; 10(8):3740-3750. PubMed ID: 31268669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.
    Wood MR; Noetzel MJ; Engers JL; Bollinger KA; Melancon BJ; Tarr JC; Han C; West M; Gregro AR; Lamsal A; Chang S; Ajmera S; Smith E; Chase P; Hodder PS; Bubser M; Jones CK; Hopkins CR; Emmitte KA; Niswender CM; Wood MW; Duggan ME; Conn PJ; Bridges TM; Lindsley CW
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3029-3033. PubMed ID: 27185330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of the M
    Vuckovic Z; Gentry PR; Berizzi AE; Hirata K; Varghese S; Thompson G; van der Westhuizen ET; Burger WAC; Rahmani R; Valant C; Langmead CJ; Lindsley CW; Baell JB; Tobin AB; Sexton PM; Christopoulos A; Thal DM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(51):26001-26007. PubMed ID: 31772027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 3-aminopicolinamides as metabotropic glutamate receptor subtype 4 (mGlu4) positive allosteric modulator warheads engendering CNS exposure and in vivo efficacy.
    Gogliotti RD; Engers DW; Garcia-Barrantes PM; Panarese JD; Gentry PR; Blobaum AL; Morrison RD; Daniels JS; Thompson AD; Jones CK; Conn PJ; Niswender CM; Lindsley CW; Hopkins CR
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2915-2919. PubMed ID: 27131990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-sulfonyl-7-azaindoline derivatives as potent, orally available and selective M(4) muscarinic acetylcholine receptor agonists.
    Suwa A; Konishi Y; Uruno Y; Takai K; Nakako T; Sakai M; Enomoto T; Ochi Y; Matsuda H; Kitamura A; Uematsu Y; Kiyoshi A; Sumiyoshi T
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2909-12. PubMed ID: 24852118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous activation of mGlu
    Cieślik P; Domin H; Chocyk A; Gruca P; Litwa E; Płoska A; Radulska A; Pelikant-Małecka I; Brański P; Kalinowski L; Wierońska JM
    Neuropharmacology; 2020 Sep; 174():107866. PubMed ID: 31785263
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.